AMGN FDA Wednesday, November 11, 2026 +0.50 Positive

Amgen Says Dazodalibep Met Primary Endpoint At Week 48

Amgen Says Dazodalibep Met Primary Endpoint At Week 48

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed